Literature DB >> 18800188

Cysteine-rich 61 (CYR61) inhibits cisplatin-induced apoptosis in ovarian carcinoma cells.

Seung Bae Rho1, Jong Soo Woo, Hyun-Jung Byun, Taehoon Chun, Sang-Yoon Park.   

Abstract

Cysteine-rich 61 (CYR61), a member of the connective tissue factor CCN (Cyr61, CTGF, Nov) family, facilitates angiogenesis by interacting with integrins. Recent observations have indicated that CYR61 also rescues cells from anti-cancer drug-mediated apoptosis but the detailed mechanism underlying the role of CYR61 during apoptosis has not been identified. To better understand the role of CYR61 during cisplatin-induced apoptosis in tumor cells, we overexpressed or inhibited CYR61 expression in human cervical cancer cells (HeLa cells) and measured cisplatin-mediated apoptosis. The results from these experiments clearly demonstrate that CYR61 prevents cisplatin-induced apoptosis by inhibiting caspase-3 activity in HeLa cells. Therefore, CYR61 may be a useful therapeutic target for cisplatin-resistant tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18800188     DOI: 10.1007/s10529-008-9845-8

Source DB:  PubMed          Journal:  Biotechnol Lett        ISSN: 0141-5492            Impact factor:   2.461


  9 in total

1.  Stromal CYR61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia.

Authors:  Xin Long; Yang Yu; Laszlo Perlaky; Tsz-Kwong Man; Michele S Redell
Journal:  Br J Haematol       Date:  2015-05-14       Impact factor: 6.998

2.  Predicting response of bladder cancers to gemcitabine and carboplatin neoadjuvant chemotherapy through genome-wide gene expression profiling.

Authors:  Yoichiro Kato; Hitoshi Zembutsu; Ryo Takata; Fuyuki Miya; Tatsuhiko Tsunoda; Wataru Obara; Tomoaki Fujioka; Yusuke Nakamura
Journal:  Exp Ther Med       Date:  2010-11-30       Impact factor: 2.447

3.  CYR61 overexpression associated with the development and poor prognosis of ovarian carcinoma.

Authors:  Huimin Shen; Muyan Cai; Shanshan Zhao; Huan Wang; Mengxiong Li; Shuzhong Yao; Nan Jiang
Journal:  Med Oncol       Date:  2014-07-22       Impact factor: 3.064

4.  Inhibiting CCN1 blocks AML cell growth by disrupting the MEK/ERK pathway.

Authors:  Chang-Chun Niu; Chen Zhao; Zhong Yang; Xiao-Li Zhang; Jing Pan; Chen Zhao; Wei-Ke Si
Journal:  Cancer Cell Int       Date:  2014-08-16       Impact factor: 5.722

5.  PKCι regulates nuclear YAP1 localization and ovarian cancer tumorigenesis.

Authors:  Y Wang; V Justilien; K I Brennan; L Jamieson; N R Murray; A P Fields
Journal:  Oncogene       Date:  2016-06-20       Impact factor: 9.867

6.  Cyr61 participates in the pathogenesis of acute lymphoblastic leukemia by enhancing cellular survival via the AKT/NF-κB signaling pathway.

Authors:  Xianjin Zhu; Yanfang Song; Conglian Wu; Chuxi Pan; Pingxia Lu; Meihua Wang; Peizheng Zheng; Rongfen Huo; Chenqing Zhang; Wanting Li; Yulin Lin; Yingping Cao; Ningli Li
Journal:  Sci Rep       Date:  2016-10-11       Impact factor: 4.379

7.  Cysteine-rich protein 61 regulates the chemosensitivity of chronic myeloid leukemia to imatinib mesylate through the nuclear factor kappa B/Bcl-2 pathway.

Authors:  Yanfang Song; Qing Lin; Zhaolian Cai; Taisen Hao; Yaohan Zhang; Xianjin Zhu
Journal:  Cancer Sci       Date:  2019-06-18       Impact factor: 6.716

8.  Cyr61 mediates oxaliplatin resistance in colorectal cancer cells by regulating Bcl-xL expression.

Authors:  Yanfang Song; Yanli Kang; Zhen Lin; Menglu Zeng; Pengchong Shi; Jia Lin; Pingxia Lu; Li Luo; Yingping Cao; Xianjin Zhu
Journal:  J Cancer       Date:  2021-01-30       Impact factor: 4.207

9.  YAP induces cisplatin resistance through activation of autophagy in human ovarian carcinoma cells.

Authors:  Lan Xiao; Xiao-Yan Shi; Ying Zhang; Ying Zhu; Lin Zhu; Wang Tian; Bing-Kun Zhu; Zhao-Lian Wei
Journal:  Onco Targets Ther       Date:  2016-03-16       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.